TY - JOUR
T1 - Potent Inhibitors of Acetyltransferase Eis Overcome Kanamycin Resistance in Mycobacterium tuberculosis
AU - Willby, Melisa J.
AU - Green, Keith D.
AU - Gajadeera, Chathurada S.
AU - Hou, Caixia
AU - Tsodikov, Oleg V.
AU - Posey, James E.
AU - Garneau-Tsodikova, Sylvie
N1 - Publisher Copyright:
© 2016 American Chemical Society.
PY - 2016/6/17
Y1 - 2016/6/17
N2 - A major cause of tuberculosis (TB) resistance to the aminoglycoside kanamycin (KAN) is the Mycobacterium tuberculosis (Mtb) acetyltransferase Eis. Upregulation of this enzyme is responsible for inactivation of KAN through acetylation of its amino groups. A 123-000-compound high-throughput screen (HTS) yielded several small-molecule Eis inhibitors that share an isothiazole S,S-dioxide heterocyclic core. These were investigated for their structure-activity relationships. Crystal structures of Eis in complex with two potent inhibitors show that these molecules are bound in the conformationally adaptable aminoglycoside binding site of the enzyme, thereby obstructing binding of KAN for acetylation. Importantly, we demonstrate that several Eis inhibitors, when used in combination with KAN against resistant Mtb, efficiently overcome KAN resistance. This approach paves the way toward development of novel combination therapies against aminoglycoside-resistant TB.
AB - A major cause of tuberculosis (TB) resistance to the aminoglycoside kanamycin (KAN) is the Mycobacterium tuberculosis (Mtb) acetyltransferase Eis. Upregulation of this enzyme is responsible for inactivation of KAN through acetylation of its amino groups. A 123-000-compound high-throughput screen (HTS) yielded several small-molecule Eis inhibitors that share an isothiazole S,S-dioxide heterocyclic core. These were investigated for their structure-activity relationships. Crystal structures of Eis in complex with two potent inhibitors show that these molecules are bound in the conformationally adaptable aminoglycoside binding site of the enzyme, thereby obstructing binding of KAN for acetylation. Importantly, we demonstrate that several Eis inhibitors, when used in combination with KAN against resistant Mtb, efficiently overcome KAN resistance. This approach paves the way toward development of novel combination therapies against aminoglycoside-resistant TB.
UR - http://www.scopus.com/inward/record.url?scp=84975246820&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84975246820&partnerID=8YFLogxK
U2 - 10.1021/acschembio.6b00110
DO - 10.1021/acschembio.6b00110
M3 - Article
C2 - 27010218
AN - SCOPUS:84975246820
SN - 1554-8929
VL - 11
SP - 1639
EP - 1646
JO - ACS Chemical Biology
JF - ACS Chemical Biology
IS - 6
ER -